A phase II study of axitinib in advanced neuroendocrine tumors

Neuroendocrine tumors (NETs) are highly vascular neoplasms overexpressing vascular endothelial growth factor (VEGF) as well as VEGF receptors (VEGFR). Axitinib is a potent, selective inhibitor of VEGFR-1, -2 and -3, currently approved for the treatment of advanced renal cell carcinoma. We performed...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Endocr Relat Cancer
Asıl Yazarlar: Strosberg, J R, Cives, M, Hwang, J, Weber, T, Nickerson, M, Atreya, C E, Venook, A, Kelley, R K, Valone, T, Morse, B, Coppola, D, Bergsland, E K
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963225/
https://ncbi.nlm.nih.gov/pubmed/27080472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-16-0008
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller